Imclone Systems

(redirected from Imclone)
Also found in: Financial.
A biopharmaceutical company which developed a portfolio of immunotherapies for colorectal and other cancers; its lead compound, Erbitux, received FDA approval after a Wall Street drama
References in periodicals archive ?
In 2004 she served five months in jail after she was convicted of lying to investigators about why she sold around [euro]200,000 of ImClone stock in 2001 just before the price plunged.
Stewart's wealth suffered massively in 2004 after she was found guilty of lying about why she sold ImClone shares just before the stock price plunged.
(Indianapolis IN) bought ImClone for $6.5 billion in 2008 and generated third-quarter revenue of $95 million from Erbitux, which is also approved to treat head and neck cancer.
The center now houses the research activities of ImClone Systems, a wholly owned subsidiary of Lilly (Lilly acquired ImClone in 2008) along with certain rights to already-marketed Erbitux and ImClone's pipeline of oncology biologics.
The new science park, located next to the NYU Langone Medical Center at 560 First Avenue at 33rd Street, will also house ImClone's Research Division, which is owned by Eli Lilly, the company said in a press release.
ImClone Systems Inc., in rejecting a $4.4 billion takeover bid by Bristol-Myers Squibb Co., reasserted its rights to an experimental cancer drug pivotal to the company's future value.
On October 31, 2001, Imclone Systems requested the government to review Erbitux, the company's new cancer drug.
ImClone Systems Incorporated (NASDAQ: IMCL), has seen global net sales of Erbitux for the fourth quarter of 2007 increase to $371 million, compared with $293 million in the fourth quarter of 2006, up 27%.
Repligen Corporation (Waltham, MA) has reached a settlement with ImClone Systems in the lawsuit against ImClone for infringement of United States Patent 4,663,281 based on ImClone's manufacture and sale of Erbitux.
ImClone Systems Incorporated (NASDAQ: IMCL), New York, has announced its financial results for the quarter and six months ended June 30, 2006.
ImClone Systems Incorporated (NASDAQ: IMCL) and UCB have entered into a worldwide strategic partnership for the development and commercialization of CDP-791, a novel, investigational antibody targeting the vascular endothelial growth factor receptor-2 (VEGFR-2) that is currently being developed by UCB.